138 related articles for article (PubMed ID: 30745733)
1. A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung.
Gupta V; Shukla S; Husain N; Kant S; Garg R
J Cytol; 2019; 36(1):13-17. PubMed ID: 30745733
[TBL] [Abstract][Full Text] [Related]
2. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma.
Zhu P; Pan Q; Wang M; Zhong W; Zhao J
Thorac Cancer; 2015 Nov; 6(6):709-14. PubMed ID: 26557908
[TBL] [Abstract][Full Text] [Related]
4.
Wang Z; Wu X; Han X; Cheng G; Mu X; Zhang Y; Cui D; Liu C; Liu D; Shi Y
Chin J Cancer Res; 2016 Dec; 28(6):606-616. PubMed ID: 28174489
[TBL] [Abstract][Full Text] [Related]
5. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
7. Discrepancies between ALK protein disruption and occurrence of
Grenda A; Jarosz B; Krawczyk P; Kucharczyk T; Wojas-Krawczyk K; Reszka K; Krukowska K; Nicoś M; Pankowski J; Bryl M; Ramlau R; Kuźnar-Kamińska B; Grodzki T; Szczęsna A; Siemiątkowska K; Szumiło J; Batura-Gabryel H; Palonka M; Milanowski J
J Thorac Dis; 2018 Aug; 10(8):4994-5009. PubMed ID: 30233874
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
9. Ventana immunohistochemistry ALK (D5F3) detection of ALK expression in pleural effusion samples of lung adenocarcinoma.
Wang Z; Wu X; Shi Y; Han X; Cheng G; Cui D; Li L; Zhang Y; Mu X; Zhang L; Yang L; Di J; Yu Q; Liu D
Per Med; 2015 Aug; 12(4):349-357. PubMed ID: 29771657
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase (ALK) mutations in patients with adenocarcinoma of the lung.
Mohamad N; Jayalakshmi P; Rhodes A; Liam CK; Tan JL; Yousoof S; Rajadurai P
Br J Biomed Sci; 2017 Oct; 74(4):176-180. PubMed ID: 28705139
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns.
Gupta P; Gowrishankar S; Swain M
Indian J Pathol Microbiol; 2019; 62(1):24-30. PubMed ID: 30706855
[TBL] [Abstract][Full Text] [Related]
12. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
13. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
[TBL] [Abstract][Full Text] [Related]
14. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
[TBL] [Abstract][Full Text] [Related]
15. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
16. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
17. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement.
Akiba J; Kawahara A; Abe H; Azuma K; Yamaguchi T; Taira T; Fukumitsu C; Takase Y; Yasumoto M; Umeno Y; Todoroki K; Kurita T; Yamaguchi R; Kage M; Yano H
Oncol Lett; 2014 Nov; 8(5):2155-2159. PubMed ID: 25295103
[TBL] [Abstract][Full Text] [Related]
19. Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
Zhou J; Zheng J; Zhao J; Sheng Y; Ding W; Zhou J
Thorac Cancer; 2015 Mar; 6(2):216-9. PubMed ID: 26273361
[TBL] [Abstract][Full Text] [Related]
20. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
